
EPRX Stock Forecast & Price Target
EPRX Analyst Ratings
Bulls say
Eupraxia Pharmaceuticals is well-positioned to capture a significant market share in the treatment of osteoarthritis and eosinophilic esophagitis symptoms with its drug EP-104. The company's proprietary Diffusphere technology sets it apart from competitors, providing a highly effective and durable treatment option, with a favorable safety profile. The recent appointment of Dr. Jeymi Tambiah, with a strong background in osteoarthritis research, further strengthens the company's potential in this area. With a clear clinical gap and potential for expansion into additional indications, Eupraxia Pharmaceuticals has a strong case for success and a promising future ahead.
Bears say
Eupraxia Pharmaceuticals is facing significant challenges with its clinical development and future commercial viability, as EP-104GI, its main product, targets niche conditions with high competition and potentially limited market demand. Additionally, the company's financials show a heavy reliance on financing and a high weighted average cost of capital, adding to the risk profile and potential for future funding difficulties. With these factors in mind, analysts have a negative outlook on the stock and believe there are significant risks to achieving the projected value and success of EP-104GI.
This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
EPRX Analyst Forecast & Price Prediction
Start investing in EPRX
Order type
Buy in
Order amount
Est. shares
0 shares